GET DAILY SIGNALSOrganogenesis (ORGO) Reports 70% Revenue Decline in Q3 as Wound Care Market Resets
Key Takeaways
- Organogenesis reported third quarter 2026 net product revenue of $45.5 million, a decline of 70% from $150.5 million a year earlier, as the Advanced Wound Care reset continued to pressure its core franchise.
- Advanced Wound Care revenue fell 73% to $38.2 million, while Surgical & Sports Medicine revenue declined 19% to $7.3 million.
- The company posted a GAAP net loss of $29.6 million, or $(0.25) per share, versus net income of $21.6 million, or $0.11 per share, in the prior-year quarter.
- Results came in below consensus, which had projected revenue of about $52.1 million and a loss per share of $(0.19).
- Despite the year-over-year decline, total revenue rose 6% sequentially, and management pointed to broad-based market share gains across the portfolio.
- The company narrowed its full-year 2026 revenue outlook to a range of $179 million to $200 million, implying a 65% to 68% decline for the year.
- For more context on Organogenesis, you can review its Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to see how AI-driven trading tools are identifying opportunities across the market.
Putting the Earnings in Context
Organogenesis is working through one of the most significant disruptions in its recent history. A broad policy shift from the Centers for Medicare & Medicaid Services has altered coverage and reimbursement for skin-substitute products, leading to a pronounced reset in the Advanced Wound Care segment that accounts for the bulk of revenue. This update gives investors a key checkpoint on whether the company can stabilize revenue, maintain margins, and hold its competitive stance as the new reimbursement environment takes hold. With revenue down sharply year over year yet up sequentially, the results test management's view that share gains in the second half of 2026 will position the business for more normalized growth ahead.
The Quarter's Reported Figures
For the third quarter ended September 30, 2026, ORGO posted net product revenue of $45.5 million, down 70% from $150.5 million in the year-ago period. Advanced Wound Care revenue dropped 73% to $38.2 million, and Surgical & Sports Medicine revenue fell 19% to $7.3 million. Both revenue and the loss per share missed analyst forecasts, which had centered on roughly $52.1 million in revenue and a $(0.19) per-share loss.
Gross profit reached $23.6 million, or 52% of net product revenue, compared with a 76% gross margin in the prior-year quarter. Operating expenses fell 42% to $74.9 million amid lower SG&A and R&D outlays, but the company still recorded an operating loss of $29.5 million versus operating income of $20.7 million a year earlier. The GAAP net loss totaled $29.6 million, or $(0.25) per share. Adjusted net loss came in at $29.3 million, and adjusted EBITDA showed a loss of $22.4 million against positive $30.1 million in the comparable quarter.
Cash, cash equivalents, and restricted cash stood at $26.9 million with no debt outstanding at quarter end, down from $94.3 million at the close of 2025. Management tightened full-year 2026 guidance to $179 million–$200 million in total net revenue, pointing to a 65%–68% year-over-year decline.
How the Market Responded
Shares of ORGO moved lower in after-hours trading after the release. The revenue and earnings misses, along with the tempered full-year outlook, overshadowed the sequential improvement. Investors continue to focus on whether the wound-care reset has reached a bottom and how rapidly share gains can translate into revenue stabilization and a return to profitability. Sentiment reflects a balance between confidence in the company's evidence-based products and ongoing questions about clinician adoption and reimbursement in the post-reset landscape. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What to Watch in the Quarters Ahead
The pace of stabilization in the Advanced Wound Care market after the CMS reimbursement changes remains the central question. Management anticipates continued sequential revenue gains in the fourth quarter and notes that share gains are broadening, though the overall revenue base sits well below prior levels.
Several items deserve close attention. Gross margin compressed to 52% this quarter as fixed costs and inventory charges weighed on a smaller revenue base. Cash and liquidity warrant monitoring, with cash at $26.9 million as the company explores financing options. Product and capacity moves, including the planned launch of Amnuvix and upgrades at the Smithfield facility, could serve as catalysts, while evidence-based living cell products stay central to long-term positioning. Expense management without eroding commercial reach will also matter as the company aims for normalized growth beyond 2026.
Leveraging AI Tools in My Research
In my own work, I often turn to Tickeron’s AI Screener when evaluating names like ORGO. The tool lets me apply technical patterns, fundamentals, and AI signals to scan the market and surface comparable setups more efficiently than manual methods. It has become a practical part of refining watchlists during earnings periods and identifying opportunities that align with specific criteria.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ORGO turns negative, indicating new downward trend
ORGO saw its Momentum Indicator move below the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 75 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ORGO entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ORGO's RSI Indicator exited the oversold zone, 24 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 67 cases where ORGO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for ORGO just turned positive on November 04, 2026. Looking at past instances where ORGO's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Following a +15.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORGO advanced for three days, in 189 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ORGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.729) is normal, around the industry mean (7.445). P/E Ratio (-1.077) is within average values for comparable stocks, (0.293). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.404) is also within normal values, averaging (181.047).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ORGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a financial conglomerate
Industry PharmaceuticalsGeneric
Advertisement